# Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

> **NCT05192941** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1770 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Inclisiran Sodium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05192941
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-08
- **Primary completion:** 2024-06-11
- **Final completion:** 2025-03-19
- **Target enrollment:** 1770 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05192941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05192941, "Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05192941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*